Berberine on the Secretion of Incretin

Diabetes Mellitus Clinical Trial

Official title:

The Effect of Berberine on the Secretion of Incretin in Normal Man

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05947370
• Other study ID #: BBR incretin
• Status: Completed
• Phase: Early Phase 1
• Start date: October 12, 2022
• Est. completion date: April 20, 2023

Study information

• Verified date: July 2023
• Source: Beijing Tongren Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Berberine (BBR) is the main active ingredient of the ancient Chinese herb medicine Coptis. The hypoglycemic effect of BBR has been demonstrated in numerous studies. Although BBR is safe and effective in the treatment of diabetes, its exact hypoglycemic mechanism is still unclear. Jin-Kui Yang found that BBR can promote GLP-1 secretion from intestinal L cells in mice in vitro and in vivo, thereby achieving the effect of lowering blood glucose, but it is still unknown whether BBR can promote incretin secretion in humans. In this study, investigators plan to examine the effect of BBR on secretion of incretin in human.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 20, 2023
• Est. primary completion date: April 6, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Voluntary participation in the trial and signed informed consent form.

2. Healthy male subjects aged 18-45 years (including 18 and 45 years).

3. No history of current or former diseases such as heart, liver, kidney, gastrointestinal tract, nervous system, respiratory system, mental disorders and metabolic abnormalities that the investigator considers meaningful; no physical examination, electrocardiogram, and laboratory examination results abnormality or abnormality has no clinical significance (subject to the judgment of the physician).

4. Body mass index of 18.0-25.0 kg/cm2 (including 18.0 and 25.0 kg/cm2) and no centripetal obesity (waist-to-hip ratio less than 0.9).

5. No family history of diabetes mellitus and obesity.

6. Normal glucose tolerance (fasting blood glucose <6.1 mmol/L and 2h blood glucose <7.8mmol/L after oral administration of 75g glucose) and normal insulin secretion function (as judged by the investigator through the results of insulin release experiment).

7. Able to communicate well with the investigator and complete the study in accordance with the study regulations.

Exclusion Criteria:

1. Infection with hepatitis (A, B, or C), HIV and syphilis.

2. Those with clear allergy to berberine hydrochloride or its preparation components; those with drug (including salicylic acid) allergy, history of allergic diseases or allergic constitution.

3. Patients with hemolytic anemia and glucose-6-phosphate dehydrogenase deficiency.

4. Those who have used any prescription medication, herbal medicine within 4 weeks prior to dosing and/or taken over-the-counter medication (except for subjects with occasional or restricted use of paracetamol), supplements (except for routine vitamin supplementation) within 2 weeks prior to dosing.

5. Cumulative amount of blood loss (eg. blood donation) over 400mL within 3 months prior to baseline visit and during the study.

6. Heavy smokers (25 or more cigarettes per day) and heavy drinkers (14 units of alcohol per week, 1 unit = 285ml of beer, or 25ml of spirits, or 100ml of wine).

7. Those with a history of substance abuse or positive urine test for prohibited drugs.

8. Those who participated in any clinical trial within 1 month prior to the trial, or those who plan to participate in other clinical trials during or within 1 month after the end of the trial.

9. Other circumstances that the investigator considers unsuitable for participation in this study.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Drug:
• Berberine Chloride
Traditional Chinese medicine
• Placebo
Placebo control

Locations

Country	Name	City	State
China	Beijing Tongren Hospital, Capital Medical University	Beijing	Beijing
China	Hao Wang	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tongren Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81. doi: 10.1016/j.jep.2014.09.049. Epub 2014 Dec 10. — View Citation

Luthra A, Misra A. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol. 2015 Oct;3(10):758-60. doi: 10.1016/S2213-8587(15)00328-9. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Differences of heart rate between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean heart rate in the two groups during glucose tolerance test.	4 hours
Other	Differences of QT-interval duration between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean QT-interval duration in the two groups during glucose tolerance test.	4 hours
Primary	Differences of serum GLP-1 levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum GLP-1 in the two groups during glucose tolerance test.	4 hours
Primary	Differences of serum GIP levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum GIP levels in the two groups during glucose tolerance test.	4 hours
Primary	Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean blood glucose levels in the two groups during glucose tolerance test.	4 hours
Secondary	Differences of serum insulin levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean insulin levels in the two groups during glucose tolerance test.	The time frame is the same as Primary Outcome Measure 1
Secondary	Differences of serum C-peptide levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum C-peptide levels in the two groups during glucose tolerance test.	4 hours
Secondary	Differences of serum potassium levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum potassium levels in the two groups during glucose tolerance test.	4 hours
Secondary	Differences of serum sodium levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum sodium levels in the two groups during glucose tolerance test.	4 hours
Secondary	Differences of serum chloride levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum chloride levels in the two groups during glucose tolerance test.	4 hours
Secondary	Differences of serum calcium levels between BBR and placebo treatment groups during the glucose tolerance test.	To compare the mean serum calcium levels in the two groups during glucose tolerance test.	4 hours